Hillevax Inc Market Cap ($104.76 Million)
Market Cap & Net Worth: Hillevax Inc (HLVX)
Hillevax Inc market cap. Hillevax Inc (NASDAQ:HLVX) has a market capitalization of $104.76 Million ($104.76 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18821 globally and #4371 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hillevax Inc's stock price $2.09 by its total outstanding shares 50125541 (50.13 Million). Also see HLVX operating cash flow for how efficiently the company converts equity into cash flow.
Hillevax Inc Market Cap History (2022–2025)
Hillevax Inc market cap history from 2022 to 2025. Data shows change from $838.60 Million to $104.76 Million (-47.94% CAGR). Check current stock price of Hillevax Inc for real-time trading data and today's change.
Index Memberships
Hillevax Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #519 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1805 of 3165 |
Weight: Hillevax Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Hillevax Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hillevax Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Hillevax Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of HLVX by Market Capitalization
Companies near Hillevax Inc in the global market cap rankings as of November 5, 2026. Also see total assets of Hillevax Inc for a full breakdown of the balance sheet.
Key companies related to Hillevax Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Hillevax Inc (2022–2025)
Market capitalization of Hillevax Inc from 2022 to today. Between 2022 and today, Hillevax Inc's market cap moved from $838.60 Million to $ 104.76 Million, with a yearly change of -47.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $104.76 Million | +0.97% |
| 2024 | $103.76 Million | -87.10% |
| 2023 | $804.51 Million | -4.06% |
| 2022 | $838.60 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Hillevax Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $104.76 Million USD |
| MoneyControl | $104.76 Million USD |
| MarketWatch | $104.76 Million USD |
| marketcap.company | $104.76 Million USD |
| Reuters | $104.76 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hillevax Inc
HilleVax, Inc., a clinical-stage biopharmaceutical company, develops and commercializes vaccines in the United States. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. It has a license agreement with Takeda Vaccines, Inc. to develop and commercialize HIL-214 pharmaceutical prod… Read more